Historical source-based research. Compilation date and financial period are different dates.
Observation
Across 11 eligible healthcare companies, the equal-weight median operating cash-flow margin was 27.32% for the prior selected annual periods.
Data context
The eligible sample covers 11 of 12 selected companies. The prior selected annual periods span 2024-12-29 to 2024-12-31. Companies have different fiscal year ends. This is a cross-sectional research sample, not a calendar-year index or a representation of the full sector.
Company evidence
LLY 19.58% (period 2024-12-31); JNJ 27.32% (period 2024-12-29); ABBV 33.38% (period 2024-12-31); MRK 33.46% (period 2024-12-31); AZN 21.94% (period 2024-12-31); AMGN 34.38% (period 2024-12-31); GILD 37.66% (period 2024-12-31); ABT 20.40% (period 2024-12-31); PFE 20.03% (period 2024-12-31); ISRG 28.91% (period 2024-12-31); VRTX -4.47% (period 2024-12-31).
Distribution
The sample range is -4.47% (VRTX) to 37.66% (GILD). The median is computed across company ratios with equal weight; it is not a ratio of aggregate totals. Extreme values can reflect a small denominator or unusual accounting items.
Interpretation
Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics. The numerator is operatingCashFlow; the denominator is revenue. Only positive denominators and disclosed numerators qualify. No missing value is replaced with zero.
What to watch
Product concentration, research investment, utilization, reimbursement and cash generation.
Research limitations
Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration. The sample uses a September 18, 2026 source snapshot. It does not establish current market conditions, causal drivers or future returns. Sector labels are editorial and the financial-sector cash-flow measures need particular caution.
| Company | Value | Period end |
|---|---|---|
| LLY | 19.58% | 2024-12-31 |
| JNJ | 27.32% | 2024-12-29 |
| ABBV | 33.38% | 2024-12-31 |
| MRK | 33.46% | 2024-12-31 |
| AZN | 21.94% | 2024-12-31 |
| AMGN | 34.38% | 2024-12-31 |
| GILD | 37.66% | 2024-12-31 |
| ABT | 20.40% | 2024-12-31 |
| PFE | 20.03% | 2024-12-31 |
| ISRG | 28.91% | 2024-12-31 |
| VRTX | -4.47% | 2024-12-31 |
Sources & dates
- LLY · period 2024-12-31 ↗Source date 2026-02-12
- JNJ · period 2024-12-29 ↗Source date 2026-02-11
- ABBV · period 2024-12-31 ↗Source date 2026-02-20
- MRK · period 2024-12-31 ↗Source date 2026-02-24
- AZN · period 2024-12-31 ↗Source date 2026-02-24
- AMGN · period 2024-12-31 ↗Source date 2026-02-13
- GILD · period 2024-12-31 ↗Source date 2026-02-24
- ABT · period 2024-12-31 ↗Source date 2026-02-20
- PFE · period 2024-12-31 ↗Source date 2026-02-26
- ISRG · period 2024-12-31 ↗Source date 2026-02-03
- VRTX · period 2024-12-31 ↗Source date 2026-02-13